Madiha Iqbal

Aug 11, 2024 | nature.com | Razan Mohty |Radhika Bansal |Urshila Durani |Madiha Iqbal |Yucai Wang |Jonas Paludo | +8 more

Dear Editor,Hemophagocytic lymphohistiocytosis (HLH) is a rare complication of chimeric antigen receptor T-cell (CAR-T) therapy [1,2,3]. With the increasing use of CAR-T therapy in treating hematological malignancies, the unique phenomenon of CAR-T-associated HLH (carHLH) is increasingly recognized. Albeit rare, reported rates vary from 1–3% to 35% depending on the underlying disease, patient population and the CAR-T product [1,2,3].

Jul 7, 2024 | nature.com | Mazyar Shadman |Madiha Iqbal |Nausheen Ahmed |Peter A. Riedell |Natalie Grover |Nilanjan Ghosh | +8 more

AbstractIn patients with relapsed DLBCL in complete remission (CR), autologous hematopoietic cell transplantation (auto-HCT) and CAR-T therapy are both effective, but it is unknown which modality provides superior outcomes. We compared the efficacy of auto-HCT vs. CAR-T in patients with DLBCL in a CR. A retrospective observational study comparing auto-HCT (2015–2021) vs. CAR-T (2018–2021) using the Center for International Blood & Marrow Transplant Research registry.